We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





Double COVID-19 Vaccine Doses May Be Needed for Guaranteed Protection from Novel Coronavirus

By HospiMedica International staff writers
Posted on 22 Jul 2020
Two doses of a COVID-19 vaccine may be required for protecting the world from the coronavirus, although doubling the number of doses for each person could make it more difficult to immunize billions of people, according to a Bloomberg report.

Amidst the pandemic, producing a COVID-19 vaccine and administering even a single-dose to everyone across the world would be a mammoth task, whereas the need for double shots is bound to increase complexities involved in manufacturing and logistics. More...
A two-shot vaccine will be tougher to distribute widely and put developing nations at a particular disadvantage. There could be even more challenges if the vaccine’s efficacy reduces over time and annual inoculation is required, as suggested by some experts.

The latest results from clinical studies of COVID-19 vaccine candidates being developed by the University of Oxford (Oxford, UK) in collaboration with AstraZeneca (Cambridgeshire, England) and by Moderna, Inc. (Cambridge, MA, USA) appear to suggest the need for a double-shot vaccine regimen. Both the COVID-19 vaccine candidates are undergoing final-stage testing with two doses, as per the Bloomberg report. However, Oxford researchers believe that some recipients may acquire protection from a single dose and the results could indicate that a single shot could provide protection for the majority of people. AstraZeneca is exploring other regimens, although the company appears to be following a two-dose strategy and the first readout of its final-stage tests is most likely to be from two doses. On the other hand, Merck (Kenilworth, NJ, USA) has been focusing purely on one-dose shots as they can be deployed more easily and seamlessly across the world in a global vaccination campaign.

Similarly, CanSino Biologics Inc.’s (Tianjin, China) fast-moving COVID-19 vaccine candidate appears to prioritize a two-dose regimen as it seems to have failed to generate a strong response in people with pre-existing immunity to the novel coronavirus used as the vector, with researchers considering the use of a booster shot three to six months after vaccination. Following the news that CanSino published Phase II results of its COVID-19 vaccine candidate Ad5-nCoV, Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, said, “With one dose, CanSino’s human adenovirus vector-based vaccine elicited receptor-binding and neutralizing antibodies in 508 patients peaking after 28 days. However, in the 52% of study participants that had a high pre-existing immunity to the viral vector, both types of antibodies were only at half the level than in the group with low-pre-existing immunity. A second dose of the vaccine might solve this issue, but on the other hand reduce the number of people who can be vaccinated.”

“Higher vaccine doses usually lead to more adverse events, so one solution might be for the elderly to generally receive two doses of the vaccine and younger people only one dose, to measure pre-existing Ad5-vector antibodies and then decide how many doses will be needed, or to add an adjuvant to boost the immune response,” added Rosenbaum.

Related Links:
University of Oxford
AstraZeneca
Moderna, Inc.
Merck
CanSino Biologics Inc.



Gold Member
12-Channel ECG
CM1200B
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Ultrasonic Dissector
SONICBEAT
New
Trocar
TAN RoTaLock Trocar
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.